{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=RO5424802", "query": { "intervention": "RO5424802" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 37, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=RO5424802&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-06T01:57:29.168Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01940510", "title": "A Study of the Effect of Multiple Doses of Rifampin on the Single Dose Pharmacokinetics of RO5424802", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteer" ], "interventions": [ { "name": "RO5424802", "type": "DRUG" }, { "name": "rifampin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 24, "start_date": "2013-10", "completion_date": "2013-10", "has_results": true, "last_update_posted_date": "2016-12-21", "last_synced_at": "2026-09-06T01:57:29.168Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01940510" }, { "nct_id": "NCT04632992", "title": "A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Unresectable or Metastatic Solid Malignancy" ], "interventions": [ { "name": "Entrectinib", "type": "DRUG" }, { "name": "Inavolisib", "type": "DRUG" }, { "name": "Alectinib", "type": "DRUG" }, { "name": "Ipatasertib", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Trastuzumab Emtansine", "type": "DRUG" }, { "name": "Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf", "type": "DRUG" }, { "name": "Tucatinib", "type": "DRUG" }, { "name": "Investigator's Choice of Chemotherapy", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Tiragolumab", "type": "DRUG" }, { "name": "Pralsetinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 252, "start_date": "2021-01-13", "completion_date": "2024-02-27", "has_results": true, "last_update_posted_date": "2025-01-08", "last_synced_at": "2026-09-06T01:57:29.168Z", "location_count": 38, "location_summary": "Anchorage, Alaska • Oro Valley, Arizona • Hot Springs, Arkansas + 33 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Oro Valley", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Encinitas", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04632992" }, { "nct_id": "NCT01801111", "title": "A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Small-Cell Lung Carcinoma" ], "interventions": [ { "name": "Erlotinib", "type": "DRUG" }, { "name": "Alectinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 138, "start_date": "2013-06-20", "completion_date": "2017-10-27", "has_results": true, "last_update_posted_date": "2018-11-02", "last_synced_at": "2026-09-06T01:57:29.168Z", "location_count": 17, "location_summary": "Birmingham, Alabama • Fullerton, California • Orange, California + 14 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fullerton", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Luis Obispo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01801111" }, { "nct_id": "NCT05987956", "title": "Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "ALK-Positive Non-Small Cell Lung Cancer (NSCLC)" ], "interventions": [ { "name": "ALECENSA - alectinib hydrochloride capsule", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "24 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "24 Years to 64 Years" }, "enrollment_count": 600, "start_date": "2026-03-18", "completion_date": "2026-12-28", "has_results": false, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-09-06T01:57:29.168Z", "location_count": 2, "location_summary": "Doral, Florida • Rockville, Maryland", "locations": [ { "city": "Doral", "state": "Florida" }, { "city": "Rockville", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05987956" }, { "nct_id": "NCT02271139", "title": "Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy", "overall_status": "NO_LONGER_AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Alectinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2017-03-09", "last_synced_at": "2026-09-06T01:57:29.168Z", "location_count": 45, "location_summary": "Bimingham, Alabama • Daphne, Alabama • Mobile, Alabama + 35 more", "locations": [ { "city": "Bimingham", "state": "Alabama" }, { "city": "Daphne", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT02271139" }, { "nct_id": "NCT04589845", "title": "Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "Entrectinib", "type": "DRUG" }, { "name": "Alectinib", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Ipatasertib", "type": "DRUG" }, { "name": "Trastuzumab emtansine", "type": "DRUG" }, { "name": "Inavolisib", "type": "DRUG" }, { "name": "Belvarafenib", "type": "DRUG" }, { "name": "Pralsetinib", "type": "DRUG" }, { "name": "Divarasib", "type": "DRUG" }, { "name": "Camonsertib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 920, "start_date": "2021-01-18", "completion_date": "2032-09-25", "has_results": false, "last_update_posted_date": "2026-09-04", "last_synced_at": "2026-09-06T01:57:29.168Z", "location_count": 32, "location_summary": "Goodyear, Arizona • Los Angeles, California • Newport Beach, California + 25 more", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04589845" }, { "nct_id": "NCT03596866", "title": "A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "ALK+ Advanced NSCLC" ], "interventions": [ { "name": "Brigatinib", "type": "DRUG" }, { "name": "Alectinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 248, "start_date": "2019-04-19", "completion_date": "2024-09-18", "has_results": true, "last_update_posted_date": "2025-09-12", "last_synced_at": "2026-09-06T01:57:29.168Z", "location_count": 4, "location_summary": "Whittier, California • Athens, Georgia • Albany, New York + 1 more", "locations": [ { "city": "Whittier", "state": "California" }, { "city": "Athens", "state": "Georgia" }, { "city": "Albany", "state": "New York" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03596866" }, { "nct_id": "NCT02521051", "title": "Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer (NSCLC)" ], "interventions": [ { "name": "Alectinib", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2015-09-28", "completion_date": "2022-04", "has_results": true, "last_update_posted_date": "2025-05-13", "last_synced_at": "2026-09-06T01:57:29.168Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02521051" }, { "nct_id": "NCT01984229", "title": "A Study of the Effects of Posaconazole on Alectinib (RO5424802) Pharmacokinetics in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteer" ], "interventions": [ { "name": "Alectinib", "type": "DRUG" }, { "name": "Posaconazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 23, "start_date": "2013-12", "completion_date": "2014-03", "has_results": true, "last_update_posted_date": "2016-10-11", "last_synced_at": "2026-09-06T01:57:29.168Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01984229" }, { "nct_id": "NCT01871805", "title": "A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Alectinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 134, "start_date": "2013-09-30", "completion_date": "2017-08-31", "has_results": true, "last_update_posted_date": "2018-08-21", "last_synced_at": "2026-09-06T01:57:29.168Z", "location_count": 39, "location_summary": "Birmingham, Alabama • Irvine, California • La Jolla, California + 32 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Irvine", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01871805" } ] }